NASDAQ:KALA KALA BIO (KALA) Stock Price, News & Analysis $4.24 -0.39 (-8.42%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$4.24 +0.00 (+0.12%) As of 04/4/2025 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About KALA BIO Stock (NASDAQ:KALA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get KALA BIO alerts:Sign Up Key Stats Today's Range$4.01▼$4.6350-Day Range$4.24▼$11.0252-Week Range$4.01▼$11.20Volume35,540 shsAverage Volume85,897 shsMarket Capitalization$25.83 millionP/E RatioN/ADividend YieldN/APrice Target$15.00Consensus RatingBuy Company OverviewKALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Read More… Remove Ads KALA BIO Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreKALA MarketRank™: KALA BIO scored higher than 72% of companies evaluated by MarketBeat, and ranked 244th out of 902 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingKALA BIO has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKALA BIO has only been the subject of 1 research reports in the past 90 days.Read more about KALA BIO's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for KALA BIO are expected to grow in the coming year, from ($10.84) to ($6.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of KALA BIO is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of KALA BIO is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKALA BIO has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about KALA BIO's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.49% of the float of KALA BIO has been sold short.Short Interest Ratio / Days to CoverKALA BIO has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in KALA BIO has recently decreased by 3.31%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKALA BIO does not currently pay a dividend.Dividend GrowthKALA BIO does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.35 Percentage of Shares Shorted5.49% of the float of KALA BIO has been sold short.Short Interest Ratio / Days to CoverKALA BIO has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in KALA BIO has recently decreased by 3.31%, indicating that investor sentiment is improving. News and Social Media2.0 / 5News Sentiment0.60 News SentimentKALA BIO has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for KALA BIO this week, compared to 2 articles on an average week. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, KALA BIO insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $72,531.00 in company stock.Percentage Held by InsidersOnly 8.32% of the stock of KALA BIO is held by insiders.Percentage Held by InstitutionsOnly 24.61% of the stock of KALA BIO is held by institutions.Read more about KALA BIO's insider trading history. Receive KALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for KALA BIO and its competitors with MarketBeat's FREE daily newsletter. Email Address KALA Stock News HeadlinesKALA BIO (KALA) to Release Quarterly Earnings on FridayApril 2, 2025 | americanbankingnews.comKALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 31, 2025 | markets.businessinsider.comTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…April 6, 2025 | Paradigm Press (Ad)KALA BIO to Present at TD Cowen 45th Annual Health Care ConferenceFebruary 26, 2025 | finance.yahoo.comKala Bio announces CEO departure, appoints interim leaderFebruary 13, 2025 | msn.comKALA BIO, Inc.: KALA BIO Announces Chief Executive Officer TransitionFebruary 12, 2025 | finanznachrichten.deKala Bio appoints new interim CEO amid leadership shuffleFebruary 12, 2025 | msn.comKala announces resignation of CEO Iwicki, Bazemore appointed interim CEOFebruary 12, 2025 | markets.businessinsider.comSee More Headlines KALA Stock Analysis - Frequently Asked Questions How have KALA shares performed this year? KALA BIO's stock was trading at $6.94 at the start of the year. Since then, KALA stock has decreased by 38.9% and is now trading at $4.24. View the best growth stocks for 2025 here. How were KALA BIO's earnings last quarter? KALA BIO, Inc. (NASDAQ:KALA) released its earnings results on Friday, March, 28th. The company reported ($1.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.28) by $0.54. When did KALA BIO's stock split? KALA BIO shares reverse split on Friday, October 21st 2022. The 1-50 reverse split was announced on Friday, October 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did KALA BIO IPO? KALA BIO (KALA) raised $90 million in an IPO on Thursday, July 20th 2017. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers. How do I buy shares of KALA BIO? Shares of KALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of KALA BIO own? Based on aggregate information from My MarketBeat watchlists, some other companies that KALA BIO investors own include Plug Power (PLUG), Ovid Therapeutics (OVID), Fortress Biotech (FBIO), FuelCell Energy (FCEL), Workhorse Group (WKHS), Lipocine (LPCN) and Comtech Telecommunications (CMTL). Company Calendar Last Earnings3/28/2025Today4/05/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KALA CIK1479419 Webwww.kalarx.com Phone(781) 996-5252Fax781-642-0399Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$15.00 Low Stock Price Target$15.00 Potential Upside/Downside+253.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($11.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,200,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-448.61% Return on Assets-69.37% Debt Debt-to-Equity Ratio3.18 Current Ratio2.15 Quick Ratio2.15 Sales & Book Value Annual Sales$3.89 million Price / Sales6.64 Cash FlowN/A Price / Cash FlowN/A Book Value$2.79 per share Price / Book1.52Miscellaneous Outstanding Shares6,091,000Free Float5,584,000Market Cap$25.83 million OptionableNot Optionable Beta-1.70 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:KALA) was last updated on 4/6/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KALA BIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KALA BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.